<SEC-DOCUMENT>0001213900-25-046800.txt : 20250522
<SEC-HEADER>0001213900-25-046800.hdr.sgml : 20250522
<ACCEPTANCE-DATETIME>20250522152010
ACCESSION NUMBER:		0001213900-25-046800
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250522
DATE AS OF CHANGE:		20250522

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-80327
		FILM NUMBER:		25976674

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Hewlett Fund LP
		CENTRAL INDEX KEY:			0001711607
		ORGANIZATION NAME:           	
		EIN:				061519205
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		100 MERRICK ROAD, SUITE 400W
		CITY:			ROCKVILLE CENTRE
		STATE:			NY
		ZIP:			11570
		BUSINESS PHONE:		516-887-6000

	MAIL ADDRESS:	
		STREET 1:		100 MERRICK ROAD, SUITE 400W
		CITY:			ROCKVILLE CENTRE
		STATE:			NY
		ZIP:			11570
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Hewlett Fund LP -->
          <cik>0001711607</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>COMMON STOCK, $0.001 PAR VALUE PER SHARE</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>05/19/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001095981</issuerCik>
        <issuerName>Plus Therapeutics, Inc.</issuerName>
        <issuerCusip>72941H509</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>2710 Reed Rd.</com:street1>
          <com:street2>Suite 160</com:street2>
          <com:city>Houston</com:city>
          <com:stateOrCountry>TX</com:stateOrCountry>
          <com:zipCode>77051</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>The Hewlett Fund LP</reportingPersonName>
      <citizenshipOrOrganization>NY</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>2006552.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2006552.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2006552.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>8.255</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
      <comments>Note to 5, 7, 9 and 11: Based on 24,307,166 shares outstanding as of May 19, 2025 as reported by the Issuer's transfer agent.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Plus Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>2710 Reed Rd., Suite 160, Houston, TX 77051</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>The Hewlett Fund LP</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>100 Merrick Road, Suite 400W, Rockville Centre, NY 11570</principalBusinessOfficeOrResidenceAddress>
        <citizenship>New York</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>2,006,552.00</amountBeneficiallyOwned>
        <classPercent>8.255%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>2,006,552.00</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0 Shares</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>2,006,552.00</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0 Shares</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>The Hewlett Fund LP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Martin Chopp</signature>
        <title>Martin Chopp, General Partner</title>
        <date>05/22/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
